Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000538539 | SCV000644497 | benign | Tuberous sclerosis 2 | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000573456 | SCV000675555 | likely benign | Hereditary cancer-predisposing syndrome | 2015-08-14 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001683572 | SCV001899994 | likely benign | not provided | 2020-10-09 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000538539 | SCV002039408 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000573456 | SCV002533484 | likely benign | Hereditary cancer-predisposing syndrome | 2021-12-28 | criteria provided, single submitter | curation | |
Fulgent Genetics, |
RCV002497151 | SCV002809238 | likely benign | Lymphangiomyomatosis; Isolated focal cortical dysplasia type II; Tuberous sclerosis 2 | 2022-03-16 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003960337 | SCV004780928 | likely benign | TSC2-related condition | 2022-05-20 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |